RT Journal Article SR Electronic T1 Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.08.21259912 DO 10.1101/2021.07.08.21259912 A1 Wanaratna, Kulthanit A1 Leethong, Pornvimol A1 Inchai, Nitapha A1 Chueawiang, Wararath A1 Sriraksa, Pantitra A1 Tabmee, Anutida A1 Sirinavin, Sayomporn YR 2021 UL http://medrxiv.org/content/early/2021/07/11/2021.07.08.21259912.abstract AB Objective To assess the efficacy and safety of Andrographis paniculata extract (APE) in adults with mild COVID-19.Methods The alcoholic extract of the aerial part of A. paniculata was used. In this randomized, double-blinded, placebo-controlled trial, adults with laboratory-confirmed COVID-19, and mild symptoms were randomized 1:1 to receive APE (60 mg andrographolide,t.i.d,for 5 days) versus placebo, plus standard supportive care. Blood tests for CRP, liver and renal assessment were performed on Days 1, 3, and 5.The outcomes were occurrence of pneumonia detected by chest X-ray, nasopharyngeal SARS-CoV-2detection by rRT-PCR, changes of CRP levels, and adverse drug reactions.Results Patients were randomized to receive APE (n=29) or placebo (n=28). Pneumonia occurrence during illness was 0/29 (0%) versus 3/28 (10.7%), (p=0.039); andpatients with nasopharyngeal SARS-CoV-2detectionon Day 5 were10/29 (34.5%) versus 16/28 (57.1%), (p=0.086), for those who received APE and placebo, respectively. All three patients with pneumonia had substantially rising serum CRP; and high CRP levels on Day 5. None had evidence of liver or renal impairment.Conclusion ThisAP-extract treatmentregimen was potentially effective and safe in adults with mild COVID-19. The rising of CRP suggested disease progression. Further studies are needed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210708001Funding StatementThe trial was supported by Thai Traditional Medical Knowledge Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethics Committee for Research in Human Subjects in the Fields of Thai Traditional and Alternative Medicine, Thailand (No.12-2563).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesManuscript Number: THEIJID-D-21-01999 Article Title: Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial. International Journal of Infectious Diseases. On Peer review process.